Target Price | CHF297.84 |
Price | CHF283.70 |
Potential | 4.98% |
Number of Estimates | 21 |
21 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF297.84. This is 4.98% higher than the current stock price. The highest price target is CHF459.90 62.11% , the lowest is CHF237.35 16.34% . | |
A rating was issued by 26 analysts: 12 Analysts recommend Roche to buy, 8 to hold and 6 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 4.98% . Most analysts recommend the Roche stock at Purchase. |
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion CHF | 60.50 | 63.08 |
3.03% | 4.27% | |
EBITDA Margin | 33.78% | 39.77% |
5.15% | 17.72% | |
Net Margin | 13.68% | 25.16% |
30.13% | 83.89% |
20 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF63.1b . This is 2.42% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF68.2b 10.74% , the lowest is CHF59.9b 2.80% .
This results in the following potential growth metrics:
2024 | CHF60.5b | 3.03% |
---|---|---|
2025 | CHF63.1b | 4.27% |
2026 | CHF65.1b | 3.28% |
2027 | CHF67.6b | 3.70% |
2028 | CHF68.8b | 1.83% |
2029 | CHF71.8b | 4.36% |
2030 | CHF76.4b | 6.43% |
2031 | CHF80.5b | 5.32% |
2032 | CHF78.9b | 1.89% |
18 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF25.1b . This is 18.68% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF27.6b 30.44% , the lowest is CHF22.3b 5.51% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | CHF20.4b | 8.34% |
---|---|---|
2025 | CHF25.1b | 22.75% |
2026 | CHF26.1b | 4.02% |
2027 | CHF27.0b | 3.36% |
2028 | CHF28.9b | 7.28% |
2029 | CHF31.0b | 7.31% |
2030 | CHF32.0b | 3.01% |
2031 | CHF33.4b | 4.57% |
2032 | CHF32.7b | 2.33% |
2024 | 33.78% | 5.15% |
---|---|---|
2025 | 39.77% | 17.72% |
2026 | 40.06% | 0.73% |
2027 | 39.92% | 0.35% |
2028 | 42.06% | 5.36% |
2029 | 43.25% | 2.83% |
2030 | 41.86% | 3.21% |
2031 | 41.57% | 0.69% |
2032 | 41.38% | 0.46% |
21 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF15.9b . This is 68.31% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF17.9b 89.35% , the lowest is CHF12.9b 37.00% .
This results in the following potential growth metrics and future Net Margins:
2024 | CHF8.3b | 28.01% |
---|---|---|
2025 | CHF15.9b | 91.73% |
2026 | CHF16.7b | 5.00% |
2027 | CHF17.6b | 5.89% |
2028 | CHF19.0b | 7.45% |
2029 | CHF20.5b | 8.12% |
2030 | CHF21.5b | 5.09% |
2031 | CHF22.7b | 5.19% |
2032 | CHF22.7b | 0.35% |
2024 | 13.68% | 30.13% |
---|---|---|
2025 | 25.16% | 83.89% |
2026 | 25.58% | 1.67% |
2027 | 26.12% | 2.11% |
2028 | 27.56% | 5.51% |
2029 | 28.55% | 3.59% |
2030 | 28.20% | 1.23% |
2031 | 28.16% | 0.14% |
2032 | 28.80% | 2.27% |
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share CHF | 10.32 | 19.94 |
27.83% | 93.22% | |
P/E | 14.31 | |
EV/Sales | 3.94 |
21 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is CHF19.94 . This is 69.70% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF22.43 90.89% , the lowest is CHF16.23 38.13% .
This results in the following potential growth metrics and future valuations:
2024 | CHF10.32 | 27.83% |
---|---|---|
2025 | CHF19.94 | 93.22% |
2026 | CHF20.93 | 4.96% |
2027 | CHF22.17 | 5.92% |
2028 | CHF23.82 | 7.44% |
2029 | CHF25.75 | 8.10% |
2030 | CHF27.06 | 5.09% |
2031 | CHF28.47 | 5.21% |
2032 | CHF28.57 | 0.35% |
Current | 24.28 | 19.78% |
---|---|---|
2025 | 14.31 | 41.06% |
2026 | 13.63 | 4.75% |
2027 | 12.87 | 5.58% |
2028 | 11.98 | 6.92% |
2029 | 11.08 | 7.51% |
2030 | 10.54 | 4.87% |
2031 | 10.02 | 4.93% |
2032 | 9.99 | 0.30% |
Based on analysts' sales estimates for 2025, the Roche stock is valued at an EV/Sales of 3.94 and an P/S ratio of 3.61 .
This results in the following potential growth metrics and future valuations:
Current | 4.04 | 3.12% |
---|---|---|
2025 | 3.94 | 2.44% |
2026 | 3.82 | 3.17% |
2027 | 3.68 | 3.57% |
2028 | 3.61 | 1.79% |
2029 | 3.46 | 4.17% |
2030 | 3.25 | 6.04% |
2031 | 3.09 | 5.05% |
2032 | 3.15 | 1.92% |
Current | 3.70 | 1.11% |
---|---|---|
2025 | 3.61 | 2.36% |
2026 | 3.49 | 3.17% |
2027 | 3.37 | 3.57% |
2028 | 3.31 | 1.80% |
2029 | 3.17 | 4.17% |
2030 | 2.98 | 6.04% |
2031 | 2.83 | 5.05% |
2032 | 2.88 | 1.92% |
Analyst | Rating | Action | Date |
---|---|---|---|
DAY BY DAY |
Hold
➜
Buy
|
Upgrade | Sep 08 2025 |
HSBC GLOBAL INVESTMENT RESEARCH |
Hold
➜
Hold
|
Unchanged | Aug 25 2025 |
TD COWEN |
Hold
➜
Hold
|
Unchanged | Aug 12 2025 |
BERENBERG |
Hold
➜
Hold
|
Unchanged | Aug 11 2025 |
ROTHSCHILD & CO REDBURN |
Buy
➜
Buy
|
Unchanged | Aug 04 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Jul 28 2025 |
LANDESBANK BADEN-WUERTTEMBERG |
Buy
➜
Buy
|
Unchanged | Jul 25 2025 |
Analyst Rating | Date |
---|---|
Upgrade
DAY BY DAY:
Hold
➜
Buy
|
Sep 08 2025 |
Unchanged
HSBC GLOBAL INVESTMENT RESEARCH:
Hold
➜
Hold
|
Aug 25 2025 |
Unchanged
TD COWEN:
Hold
➜
Hold
|
Aug 12 2025 |
Unchanged
BERENBERG:
Hold
➜
Hold
|
Aug 11 2025 |
Unchanged
ROTHSCHILD & CO REDBURN:
Buy
➜
Buy
|
Aug 04 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Jul 28 2025 |
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Buy
➜
Buy
|
Jul 25 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.